Clusterin decreases hepatic SREBP-1c expression and lipid accumulation - PubMed (original) (raw)

. 2013 May;154(5):1722-30.

doi: 10.1210/en.2012-2009. Epub 2013 Mar 20.

Affiliations

• PMID: 23515283
• DOI: 10.1210/en.2012-2009

Clusterin decreases hepatic SREBP-1c expression and lipid accumulation

Hye-Young Seo et al. Endocrinology. 2013 May.

Erratum in

• Endocrinology. 2013 Jun;154(6):2254

Abstract

Hepatic steatosis is emerging as the most important cause of chronic liver disease and is associated with the increasing incidence of obesity with insulin resistance. Sterol regulatory binding protein-1c (SREBP-1c) is a master regulator of lipogenic gene expression in the liver. Hyperinsulinemia induces SREBP-1c transcription through liver X receptor (LXR), specificity protein 1, and SREBP-1c itself. Clusterin, an 80-kDa disulfide-linked heterodimeric protein, has been functionally implicated in several physiological processes including lipid transport; however, little is known about its effect on hepatic lipogenesis. The present study examined whether clusterin regulates SREBP-1c expression and lipid accumulation in the liver. Adenovirus-mediated overexpression of clusterin inhibited insulin- or LXR agonist-stimulated SREBP-1c expression in cultured liver cells. In reporter assays, clusterin inhibited SREBP-1c promoter activity. Moreover, adenovirus-mediated overexpression of clusterin in the livers of mice fed a high-fat diet inhibited hepatic steatosis through the inhibition of SREBP-1c expression. Reporter and gel shift assays showed that clusterin inhibits SREBP-1c expression via the repression of LXR and specificity protein 1 activity. This study shows that clusterin inhibits hepatic lipid accumulation through the inhibition of SREBP-1c expression and suggests that clusterin is a negative regulator of SREBP-1c expression and hepatic lipogenesis.

PubMed Disclaimer

Similar articles

• Cilostazol inhibits insulin-stimulated expression of sterol regulatory binding protein-1c via inhibition of LXR and Sp1.
  Jung YA, Kim HK, Bae KH, Seo HY, Kim HS, Jang BK, Jung GS, Lee IK, Kim MK, Park KG. Jung YA, et al. Exp Mol Med. 2014 Jan 24;46(1):e73. doi: 10.1038/emm.2013.143. Exp Mol Med. 2014. PMID: 24458133 Free PMC article.
• Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE.
  Lee JM, Gang GT, Kim DK, Kim YD, Koo SH, Lee CH, Choi HS. Lee JM, et al. J Biol Chem. 2014 Jan 10;289(2):1079-91. doi: 10.1074/jbc.M113.491522. Epub 2013 Nov 21. J Biol Chem. 2014. PMID: 24265317 Free PMC article.
• Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
  Yan F, Wang Q, Lu M, Chen W, Song Y, Jing F, Guan Y, Wang L, Lin Y, Bo T, Zhang J, Wang T, Xin W, Yu C, Guan Q, Zhou X, Gao L, Xu C, Zhao J. Yan F, et al. J Hepatol. 2014 Dec;61(6):1358-64. doi: 10.1016/j.jhep.2014.06.037. Epub 2014 Jul 10. J Hepatol. 2014. PMID: 25016220
• Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c.
  Ferré P, Foufelle F. Ferré P, et al. Diabetes Obes Metab. 2010 Oct;12 Suppl 2:83-92. doi: 10.1111/j.1463-1326.2010.01275.x. Diabetes Obes Metab. 2010. PMID: 21029304 Review.
• SREBP-1c transcription factor and lipid homeostasis: clinical perspective.
  Ferré P, Foufelle F. Ferré P, et al. Horm Res. 2007;68(2):72-82. doi: 10.1159/000100426. Epub 2007 Mar 5. Horm Res. 2007. PMID: 17344645 Review.

Cited by

• ASGR1 deficiency diverts lipids toward adipose tissue but results in liver damage during obesity.
  Svecla M, Da Dalt L, Moregola A, Nour J, Baragetti A, Uboldi P, Donetti E, Arnaboldi L, Beretta G, Bonacina F, Norata GD. Svecla M, et al. Cardiovasc Diabetol. 2024 Jan 28;23(1):42. doi: 10.1186/s12933-023-02099-6. Cardiovasc Diabetol. 2024. PMID: 38281933 Free PMC article.
• Associations between serum clusterin levels and non-alcoholic fatty liver disease.
  Wang Y, Shen Y, Hu T, Wang Y, Ma X, Yu H, Bao Y. Wang Y, et al. Endocr Connect. 2023 Jun 12;12(7):e220545. doi: 10.1530/EC-22-0545. Print 2023 Jul 1. Endocr Connect. 2023. PMID: 37043769 Free PMC article.
• The clusterin connectome: Emerging players in chondrocyte biology and putative exploratory biomarkers of osteoarthritis.
  Kovács P, Pushparaj PN, Takács R, Mobasheri A, Matta C. Kovács P, et al. Front Immunol. 2023 Mar 15;14:1103097. doi: 10.3389/fimmu.2023.1103097. eCollection 2023. Front Immunol. 2023. PMID: 37033956 Free PMC article.
• Human milk-derived extracellular vesicles alleviate high fat diet-induced non-alcoholic fatty liver disease in mice.
  Jiang X, Wu Y, Zhong H, Zhang X, Sun X, Liu L, Cui X, Chi X, Ji C. Jiang X, et al. Mol Biol Rep. 2023 Mar;50(3):2257-2268. doi: 10.1007/s11033-022-08206-2. Epub 2022 Dec 27. Mol Biol Rep. 2023. PMID: 36575319
• Sterol O-acyltransferase 2 chaperoned by apolipoprotein J facilitates hepatic lipid accumulation following viral and nutrient stresses.
  Sun HY, Chen TY, Tan YC, Wang CH, Young KC. Sun HY, et al. Commun Biol. 2021 May 12;4(1):564. doi: 10.1038/s42003-021-02093-2. Commun Biol. 2021. PMID: 33980978 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • scite Smart Citations

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)

• Research Materials

  • NCI CPTC Antibody Characterization Program